Table 2.
Measure | 89Zr-rituximab | 89Zr-cetuximab | 89Zr-trastuzumab | All | ||
---|---|---|---|---|---|---|
D3 | D6 | D3 | D6 | D4 | ||
% of VOI changed by ≥1 observer after viewing the 18F-FDG-PET | 19% | 34% | 0% | 10% | 31%a | 25% |
% of VOI accepted after semi-automatic delineation | 58% | 66% | 14% | 30% | 21% | 45% |
aNo 18F-FDG-PET available for patient 17